



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Granzyme B Recombinant Monoclonal Antibody [BLR022E]

Rabbit Recombinant Monoclonal

Purified RefSeq ID NP_004122.2
Catalog No. A700-022CF Uniprot ID P10144
Lot No. A700-022CF-3

SPECIES REACTIVITY Human
AMOUNT 100 µl
CONCENTRATION 1000 µg/ml
STORAGE/SHELF LIFE 2 - 8°C / 1 year from date of receipt
PHYSICAL STATE Liquid
BUFFER Borate Buffered Saline (BBS) pH 8.2 with 0.09% Sodium Azide, BSA Free
ISOTYPE IgG
CLONE # BLR022E
ORIGIN USA

PRODUCTION PROCEDURES The monoclonal antibody was purified from cell culture supernatant.

Immunogen was a recombinant protein representing human Granzyme B (residues 19-247, NP_004122.2).

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

A700-022CF is the carrier-free version of RMAB466-7F11, which is qualified for use in Western Blot, Immunoprecipitation, Immunohistochemistry, and/or Immunocytochemistry. The format of A700-022CF is designed for compatibility with the labeling of the antibody such as with fluorochromes, metal isotopes, oligonucleotides, and enzymes. Upon completion of labeling, the user must empirically define the assay dependent concentration for use.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: September 29, 2022